Managing ADC Toxicities and Infusion Reactions With Supportive Care Strategies

EP: 1.Navigating HER2 Heterogeneity: Precision Pathways in Breast Cancer Treatment

EP: 2.Metastatic Breast Cancer Treatment Guidelines and the Nuances of HER2-Low Disease in Clinical Practice

EP: 3.Transforming Breast Cancer Treatment Through ADC-Targeting Mechanisms

EP: 4.How ADC Design Influences Efficacy and Safety

EP: 5.Beyond HER2: Expanding the Biomarker Testing Landscape in Metastatic Breast Cancer

EP: 6.Comparing Approved ADC Options in HER2-Negative and HER2-Low Breast Cancer

EP: 7.Key Considerations for Oncology Pharmacists When Selecting and Sequencing ADC Therapies

EP: 8.Emerging ADC Clinical Trial Evidence in Breast Cancer Treatment

EP: 9.Personalizing ADC Therapy in mBC Based on Patient Characteristics and Prior Therapies

EP: 10.Practical Insights for Pharmacists on ADC Administration, Patient Experience, and Supportive Care

Now Viewing

EP: 11.Managing ADC Toxicities and Infusion Reactions With Supportive Care Strategies

EP: 12.Monitoring Strategies for Managing ADC Toxicities in mBC

EP: 13.Optimizing ADC Supportive Care Prescribing and AE Management With Institutional Workflows

EP: 14.Discussing ADC Risks, Benefits, and Regimens With Patients

EP: 15.Interdisciplinary Approaches to Breast Cancer Care and ADC Treatment Barriers Due to Social Determinants of Health

EP: 16.Concluding Remarks: Collaborative Expertise in an Era of Emerging Cancer Therapies

Video content above has been prompted by the following:

• Current ADCs in this space have fairly toxic AE profiles. What supportive care agents do you utilize when treating a patient with ADC therapy?
• In your practice, how do you address the potential for infusion-related reactions, and how do you manage their occurrence?